MABXIENCE
mAbxience is a biotechnology company specialising in the research, development and manufacture of biologic products, mainly biosimilar drugs. Established in Europe in 2009, they are a multinational group that operates internationally and enjoys a strong presence in the major pharmaceutical markets. mAbxience is also fully committed to high-quality products and processes that meet regulatory and technical requirements in all countries in which they operate. They currently have two fully developed biosimilars already marketed as well as four in the developmental phase.
MABXIENCE
Industry:
Biopharma Biotechnology
Founded:
2009-01-01
Address:
Lugano, Ticino, Switzerland
Country:
Switzerland
Website Url:
http://www.mabxience.com
Total Employee:
101+
Status:
Active
Contact:
+41 91 973 14 23
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics WordPress Content Delivery Network Google Universal Analytics Font Awesome Wordpress Plugins
Similar Organizations
Agro Diagnostic
Agro Diagnostic is a laboratory specializing in research and development, pathological analysis and monitoring of plant's health.
BioVendor Group
BioVendor Group is an internationally operating group of companies with its own research & development and manufacturing capability.
Dyax
Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Marinomed
Marinomed is a biopharmaceutical company that develops innovative anti-viral and immunological treatments.
Current Employees Featured
Founder
Official Site Inspections
http://www.mabxience.com Semrush global rank: 2.28 M Semrush visits lastest month: 8.32 K
- Host name: 45.60.249.89
- IP address: 45.60.249.89
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "mAbxience"
mAbxience
We are a leading vertically integrated biopharmaceuticals company, committed to improving patient access to treatments worldwide. Our in-house, core R&D competencies set us apart in the development of biosimilars and innovator …See details»
About us - mAbxience
With over a decade of experience, mAbxience is a global biotech company dedicated to the development and manufacture of biologics, supporting access to high-quality medicines. We provide end-to-end services in the B2B …See details»
Biopharmaceutical development - mAbxience
We are specialists in biologics: we have developed and commercialized two biosimilar medicines for oncology, available to thousands of patients across the globe via our B2B partnerships in worldwide markets: MB01 rituximab …See details»
mAbxience - Crunchbase Company Profile & Funding
MAbxience is a biotechnology company specialising in the research, development and manufacture of biologic products, mainly biosimilar drugs. Established in Europe in 2009, they …See details»
mAbxience - LinkedIn
MAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. With over a decade of expertise, our mission is clear: to provide...See details»
mAbxience - LinkedIn
At mAbxience, our mission is to make high-quality medicines available worldwide by overcoming the unique challenges of biosimilar production. From navigating complex regulatory pathways …See details»
mAbxience | LinkedIn
MAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. With over a decade of expertise, our mission is …See details»
mAbxience - The Org
MAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to …See details»
Fresenius Kabi completes majority stake acquisition of …
Aug 1, 2022 · Fresenius Kabi closed the majority stake acquisition of mAbxience Holding S.L. (“mAbxience”), a leading international biopharmaceutical company. The transaction was previously announced on March 31, 2022.See details»
mAbxience Company Profile 2024: Valuation, Investors, …
Operator of a biopharmaceutical company dedicated to contributing to the sustainability of healthcare systems worldwide.See details»
Fresenius Kabi acquires mAbxience majority stake
Mar 31, 2022 · Fresenius Kabi closed the majority stake acquisition of mAbxience Holding S.L. (“mAbxience”), a leading international biopharmaceutical company. The transaction was …See details»
Fresenius Kabi completes acquisition of majority stake in mAbxience
Aug 1, 2022 · Fresenius Kabi closed the majority stake acquisition of mAbxience Holding S.L. (“mAbxience”), a leading international biopharmaceutical company. The transaction was …See details»
Emmanuelle Lepine, CEO, mAbxience - PharmaBoardroom
Dec 20, 2021 · mAbxience’s CEO Emmanuelle Lepine highlights the company’s international expansion into highly regulated markets, new investment into its Spanish manufacturing …See details»
mAbxience Company Profile - Office Locations, Competitors, …
MAbxience is a biopharmaceutical company specializing in research, development, and manufacturing of biosimilars. It offers monoclonal antibody biosimilars for the areas of …See details»
Abbott Broadens Access to Cutting-Edge Biosimilars in Key …
ABBOTT PARK, Ill., Sept. 20, 2023 / PRNewswire / -- Abbott (NYSE: ABT) announced today an agreement with Spain -based global biotech leader mAbxience Holdings S.L. to commercialize …See details»
CDMO services - mAbxience
We are a global CDMO with 14+ years of patient-centric experience in the development and manufacture of biopharmaceuticals. We offer a personalized service and our commitment to …See details»
Fresenius Kabi buys a majority stake in mAbxience and acquires …
Mar 31, 2022 · Fresenius Kabi announced today that it has agreed to acquire a stake of 55% of mAbxience Holding S.L. (”mAbxience”). The purchase price will be a combination of €495 …See details»
Formulation Development - mAbxience
Our formulations are customized for a wide range of biopharmaceuticals, prioritizing both product stability and patient safety. We excel in developing high-concentration formulations for …See details»
MABXIENCE | VentureRadar
MAbxience is a biotechnology company specialising in the research, development and manufacture of biologic products, mainly biosimilar drugs. ... Find out more about …See details»
Media center - mAbxience
May 9, 2024 · Single-use technology: how efficient is the present and future of biopharma manufacturing?See details»